MONITORING TARGETED DRUGS
High-affinity tests that monitor the use of onco-therapeutics that support cancer treatment de-escalation to achieve better outcomes with less drug, less cost and improved quality of life.
The introduction of targeted cancer drugs fulfilled the promise of personalized (precision) medicine, offering great benefit to some patients, great expense to others.
Martell was organized to launch the next paradigm—how best to manage precision treatments. This can be accomplished with inexpensive blood tests (tumor biomarker tests) that quickly document drug efficacy, remission and recurrence. We consider our mission de-escalation: less medication, less cost and a better quality of life.